drugset / Trial / NCT03057314

Improving Function,Welfare of Late-stage Cancer Subjects by ACC

NCT03057314 ↗

Phase 1 Terminated 10 enrolled Amorphical Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To improve the function and welfare of late stage solid cancer subjects by: * enabling subjects to benefit from a potentially promising drug under development * assessing initial evidence of improvement in Pain VAS score * assessing initial improvement in Performance Status (PS) * assessing initial improvement in oxygen saturation whenever it is feasible

Timeline

Start
2017-06-25
Primary completion
2019-12-31
Completion
2019-12-31

Outcome

Outcome not reported

Stopped: “Slow recreuitment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Amorphous Calcium Carbonate Unknown 1 % Oral
Subject Amorphous Calcium Carbonate Unknown 200 mg Oral

Indications